Stock Events

Stock Events

IO Biotech 

$0.006900
52
+$0.00+40.82% Monday 19:43

Statistics

Day High
0.008
Day Low
0.006
52W High
2.79
52W Low
0.001
Volume
155,500
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

14NovExpected
Q4 0
Q3 2025
-0.32
-0.26
-0.19
-0.13
Expected EPS
-0.324
Actual EPS
-0.13

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IOBTQ. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BioNTech
BNTX
Mkt Cap22.9B
BioNTech SE is a competitor because it also focuses on developing immunotherapies for cancer and other serious diseases, similar to IO Biotech's focus on novel immune-modulating cancer therapies.
Moderna
MRNA
Mkt Cap19.8B
Moderna, Inc. is involved in creating mRNA-based therapies, including cancer vaccines, which puts it in direct competition with IO Biotech's immunotherapy research.
Novavax
NVAX
Mkt Cap1.46B
Novavax, Inc. competes in the development of vaccines for serious infectious diseases but its technology and approach to stimulating immune responses can be seen as competitive to IO Biotech's work in cancer immunotherapy.
Gilead Sciences
GILD
Mkt Cap155.93B
Gilead Sciences, Inc. has a broad portfolio including oncology, making it a competitor due to its involvement in developing treatments for cancer, similar to IO Biotech's focus.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. is a biotechnology company with efforts in oncology and therapeutics that could compete with IO Biotech's cancer immunotherapy products.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. has a diverse range of biopharmaceutical products, including cancer treatments, making it a competitor in the oncology space alongside IO Biotech.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol-Myers Squibb Company is heavily involved in cancer research and drug development, positioning it as a competitor to IO Biotech in the oncology market.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. is a leading pharmaceutical company with a strong emphasis on cancer treatments, including immunotherapy, making it a direct competitor to IO Biotech.
Roche
RHHBY
Mkt Cap332.67B
Roche Holding AG engages in the research and development of medical drugs, including cancer immunotherapies, which competes with IO Biotech's focus area.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC is involved in the discovery and development of new cancer treatments, including immunotherapies, making it a competitor in the same field as IO Biotech.

About

IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1). This candidate is progressing through Phase 2 clinical trials for melanoma and is also being evaluated in Phase 1 trials across a range of other cancers, including lung, head and neck, bladder, and melanoma. Additionally, IO Biotech is developing IO112, a distinct product candidate. IO112 comprises a single Arginase 1-derived peptide designed to specifically target T cells that identify epitopes originating from Arginase 1, aiming to treat various malignancies. Established in 2014, the company is headquartered in Copenhagen, Denmark.
Show more...
CEO
Country
United States
ISIN
US4497781090

Listings

OTC Link
US
IOBTQ
XNAS
US
IOBT
BOATS
BOATS
IOBT.BOATS

0 Comments

Share your thoughts

FAQ

What is IO Biotech stock price today?▼
The current price of IOBTQ is $0.01 USD — it has increased by +40.82% in the past 24 hours. Watch IO Biotech stock price performance more closely on the chart.
What is IO Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange IO Biotech stocks are traded under the ticker IOBTQ.
What were IO Biotech earnings last quarter?▼
IOBTQ earnings for the last quarter are -0.13 USD per share, whereas the estimation was -0.32 USD resulting in a +59.88% surprise. The estimated earnings for the next quarter are N/A USD per share.
In which sector is IO Biotech located?▼
IO Biotech operates in the Other sector.
When did IO Biotech complete a stock split?▼
IO Biotech has not had any recent stock splits.
Where is IO Biotech headquartered?▼
IO Biotech is headquartered in Copenhagen, United States.